These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34386604)

  • 1. The ultrasound-guided attenuation parameter is useful in quantification of hepatic steatosis in non-alcoholic fatty liver disease.
    Ogino Y; Wakui N; Nagai H; Igarashi Y
    JGH Open; 2021 Aug; 5(8):947-952. PubMed ID: 34386604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease.
    Kuroda H; Abe T; Fujiwara Y; Nagasawa T; Takikawa Y
    J Med Ultrason (2001); 2021 Oct; 48(4):471-480. PubMed ID: 34415481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
    Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
    Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Ultrasound-Guided Attenuation Parameter for the Detection and Quantification of Hepatic Steatosis in Patients with Fatty Liver Diagnosed by Computed Tomography.
    Iwashita H; Shakado S; Yoshimaru N; Tanaka H; Koto F; Tanaka T; Takata K; Yokoyama K; Yamaguchi M; Irie M; Hirai F
    Ultrasound Med Biol; 2022 Jul; 48(7):1282-1289. PubMed ID: 35397929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation and Performance of three Ultrasound Techniques to Stage Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
    Shen Q; Hao Y; Chen J; Liu Q; Jia H; Liu L
    Curr Med Imaging; 2024; 20():1-12. PubMed ID: 38389362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort.
    Dioguardi Burgio M; Ronot M; Reizine E; Rautou PE; Castera L; Paradis V; Garteiser P; Van Beers B; Vilgrain V
    Eur Radiol; 2020 Apr; 30(4):2293-2301. PubMed ID: 31822978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis?
    Seo DM; Lee SM; Park JW; Kim MJ; Ha HI; Park SY; Lee K
    Ultrasonography; 2023 Apr; 42(2):227-237. PubMed ID: 36935602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease.
    Fujiwara Y; Kuroda H; Abe T; Ishida K; Oguri T; Noguchi S; Sugai T; Kamiyama N; Takikawa Y
    Ultrasound Med Biol; 2018 Nov; 44(11):2223-2232. PubMed ID: 30077415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience.
    Baumeler S; Jochum W; Neuweiler J; Bergamin I; Semela D
    Swiss Med Wkly; 2019 Apr; 149():w20077. PubMed ID: 31026041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
    Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
    J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation.
    Welman CJ; Saunders J; Zelesco M; Abbott S; Boardman G; Ayonrinde OT
    J Med Imaging Radiat Oncol; 2023 Feb; 67(1):45-53. PubMed ID: 35466506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis.
    Jang JK; Kim SY; Yoo IW; Cho YB; Kang HJ; Lee DH
    Eur Radiol; 2022 Mar; 32(3):2070-2077. PubMed ID: 34549325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study.
    Jiang M; Zhang X; Wu X; Xu Z; Pan J; He H; Luo Y; Chen J
    Ann Transl Med; 2023 Jan; 11(2):38. PubMed ID: 36819532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes.
    Dioguardi Burgio M; Castera L; Oufighou M; Rautou PE; Paradis V; Bedossa P; Sartoris R; Ronot M; Bodard S; Garteiser P; Van Beers B; Valla D; Vilgrain V; Correas JM;
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1005-1013.e27. PubMed ID: 38072287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
    Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of a novel ultrasound-based quantitative method to assess liver steatosis in histologically identified nonalcoholic fatty liver disease.
    Kang KA; Lee SR; Jun DW; Do IG; Kim MS
    Med Ultrason; 2023 Mar; 25(1):7-13. PubMed ID: 36780603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.
    Chan WK; Nik Mustapha NR; Wong GL; Wong VW; Mahadeva S
    United European Gastroenterol J; 2017 Feb; 5(1):76-85. PubMed ID: 28405325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.